002620 — Jeil Pharma Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Market Cap
KR₩152bn
Enterprise Value
KR₩333bn
Revenue
KR₩804bn

Annual income statement for Jeil Pharma Holdings, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	R2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	731,805	761,997	762,568	792,965	804,043
Cost of Revenue
Gross Profit	182,501	191,239	180,507	180,483	214,584
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	819,829	738,872	786,423	878,848	811,826
Operating Profit	-88,024	23,125	-23,855	-85,883	-7,783
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-82,213	30,822	-6,129	-83,861	-13,982
Provision for Income Taxes
Net Income After Taxes	-95,509	14,941	-12,870	-83,145	-13,241
Minority Interest
Net Income Before Extraordinary Items
Net Income	-90,492	11,431	-3,482	-74,556	-16,250
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-90,492	11,431	-3,482	-74,556	-16,250
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1,764	724	402	-1,541	152
Dividends per Share